| Literature DB >> 28822064 |
Wahiba Elhag1, Walid El Ansari2,3,4, Sama Abdulrazzaq1, Ali Abdullah5, Mohamed Elsherif1, Israa Elgenaied1.
Abstract
BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is a popular treatment for adolescent morbid obesity. Research on LSG outcomes among adolescents assessed a narrow range of anthropometric, nutritional, or cardiometabolic parameters, leading to an incomplete picture of these changes. We examined a wide variety of anthropometric, nutritional, and cardiometabolic parameters among adolescents before and after LSG.Entities:
Keywords: Adolescents; Bariatric surgery; Cardio metabolic risk factors; Macronutrients; Nutrient deficiency; Obesity; Sleeve gastrectomy
Mesh:
Year: 2018 PMID: 28822064 PMCID: PMC5778185 DOI: 10.1007/s11695-017-2868-2
Source DB: PubMed Journal: Obes Surg ISSN: 0960-8923 Impact factor: 4.129
Mean preoperative and postoperative anthropometric values of the study sample
| Parameter | Preop | Postopa
|
| Difference |
|---|---|---|---|---|
| Weight | 126.15 (22.76) | 78.5 (13.17) | < 0.0001 | 51.82 (28.05) |
| BMI (kg/m2) | 46.04 (5.99) | 28.30 (6.07) | < 0.0001 | 17 (6.24) |
| EW (kg) | 66 (19.54) | 21 (14.9) | < 0.0001 | 47.94 (19.84) |
| EWL (%) | – | 81.08 (19.65) | – | – |
M mean, SD standard deviation, Difference preop value minus postop value, BMI body mass index, EW excess weight, EWL (%) excess weight loss (%), — not applicable
aMeasured at a mean of 24.2 months
Preoperative and postoperative mean values of nutritional parameters
| Parameter | Normal values (unit) | Preop | Postopa | Difference |
|
|---|---|---|---|---|---|
|
|
| ||||
| Hemoglobin | |||||
| Male | 13.8–16 (mg/dL) | 14.10 ± 1.25 | 14.43 ± 2.01 | 0.28 ± 1.9 | 0.40 |
| Female | 12.1–16 (mg/dL) | 12.52 ± 1.15 | 12.29 ± 1.34 | 0.22 ± 1.1 | 0.17 |
| Hematocrit | |||||
| Male | 34.8–43.9 (%) | 43.3 ± 2.93 | 44.79 ± 2.42 | 1.3 ± 2.8 | 0.01 |
| Female | 34–40.7 (%) | 38.73 ± 2.89 | 38.01 ± 3.68 | − 0.74 ± 3.74 | 0.21 |
| MCV | 83–101 (f/L) | 81.16 ± 6.03 | 83.45 ± 6.68 | 2.29 ± 4.12 | < 0.0001 |
| Iron | 5.4–28.6 (μmol/L) | 10.31 ± 4.87 | 15.11 ± 7.87 | 4.80 ± 4.89 | < 0.0001 |
| Ferritin | 11–304 (mcg/L) | 29.50 ± 25.19 | 34.72 ± 37.79 | 5.22 ± 25.62 | 0.64 |
| Total protein | 64–83 (g/L) | 73 ± 4.16 | 69.88 ± 4.63 | − 3.13 ± 5.36 | < 0.0001 |
| Albumin | 40–150 (mg/L) | 41.14 ± 4.06 | 40.38 ± 4.67 | − 0.77 ± 4.16 | 0.13 |
| Calcium | 2.1–2.5 (mmol/L) | 2.28 ± 0.12 | 2.55 ± 1.79 | 0.28 ± 1.81 | 0.32 |
| Magnesium | 0.72–1.04 (mmol/L) | 0.81 ± 0.04 | 0.81 ± 0.04 | 0.00 ± 0.06 | 0.91 |
| Phosphate | 0.89–1.66 (mmol/L) | 1.55 ± 0.22 | 1.50 ± 0.19 | − 0.05 ± 0.15 | 0.40 |
| Zinc | 10.1–16.8 (μmol/L) | 12.75 ± 1.25 | 11.98 ± 1.22 | − 0.77 ± 1.84 | 0.28 |
| Copper | 11–22 (μmol/L) | 21.32 ± 2.26 | 16.87 ± 3.45 | − 4.45 ± 3.91 | 0.04 |
| Vitamin D | 30–50 (ng/mL) | 11.73 ± 6.06 | 17.73 ± 9.33 | 6.00 ± 11.11 | < 0.0001 |
| Vitamin B12 | 133–675 (pmol/L) | 256.51 ± 106.71 | 271.22 ± 227.64 | − 14.71 ± 229.17 | 0.036 |
| Folic acid | 4–45 (nmol/L) | 20.41 ± 11.30 | 14.40 ± 10.74 | − 6.01 ± 12.42 | 0.07 |
M mean, SD standard deviation, Difference postoperative value minus preoperative value, MCV mean cell volume
aMean follow-up = 24.2 ± 12.28 months
Evolution of nutritional deficiencies among the study sample
| Parameter | Preop | Postopa
|
| De novo |
|---|---|---|---|---|
| Hemoglobin | ||||
| Male | 13 (39.4) | 5 (15.2) | 0.02 | 1 (3.0) |
| Female | 13 (31.7) | 12 (29.3) | 0.99 | 4 (9.8) |
| Hematocrit | ||||
| Male | 0 (0) | 2 (5.9) | NA | 5 (5.9) |
| Female | 2 (4.9) | 4 (9.8) | 0.69 | 4 (9.8) |
| MCV (micro def.)d | ||||
| Male | 7 (20.6) | 2 (5.9) | 0.06 | 0 (0) |
| Female | 11 (27.5) | 8 (20) | 0.45 | 2 (5) |
| Iron | 5 (20.8) | 4 (16.7) | 0.99 | 1 (4.2) |
| Ferritin | 2 (33.3) | 2 (33.3) | 0.99 | 1 (16.7) |
| Total protein | 0 (0) | 3 (4.6) | NA | 3 (4.6) |
| Albumin | 21 (29.6) | 27 (38) | 0.29 | 14 (19.7) |
| Calcium | 2 (4.7) | 2 (4.7) | 0.99 | 1 (2.3) |
| Magnesium | 0 (0) | 0 (0) | NA | 0 (0) |
| Phosphate | 0 (0) | 0 (0) | NA | 0 (0) |
| Zinc | 0 (0) | 0 (0) | NA | 0 (0) |
| Copper | 0 (0) | 1 (16.7) | NA | 1 (16.7) |
| Vitamin D | 54 (96.4) | 50 (89.3) | 0.29 | 2 (3.6) |
| Vitamin B12 | 3 (6.7) | 6 (15.3) | 0.38 | 4 (8.9) |
| Folic acid | 0 (0) | 0 (0) | NA | 0 (0) |
N number, NA not applicable, MCV mean cell volume
aMean follow-up = 24.2 ± 12.28 months
bMcNemar chi-squared test
cPercentage of participants with deficiency calculated as the number of participants (among those for whom sufficient data were available both preoperatively and postoperatively to determine whether the coexisting condition was present), divided by the number of participants (among those for whom sufficient data were available preoperatively and postoperatively)
dRepresenting microcytic deficiency (MCV < 83) in anemic patients only (i.e., patient with deficient hemoglobin levels)
Preoperative and postoperative mean values of cardiometabolic parameters
| Parameter | Normal value (unit) | Preop | Postopa
| Difference |
|
|---|---|---|---|---|---|
| TC | < 5.17 (mmol/L) | 4.57 ± 0.74 | 4.28 ± 0.61 | 0.29 ± 0.78 | 0.02 |
| LDL | < 3.36 (mmol/L) | 2.92 ± 0.78 | 2.67 ± 0.66 | 0.26 ± 0.73 | 0.04 |
| HDL | > 1 (mmol/L) | 1.14 ± 0.26 | 1.29 ± 0.33 | − 0.14 ± 0.27 | 0.003 |
| TG | < 1.7 (mmol/L) | 1.13 ± 0.47 | 0.83 ± 0.41 | 0.30 ± 0.50 | 0.001 |
| ALT | 9–24 (U/L) | 31.03 ± 19.54 | 17.68 ± 15.67 | 13.35 ± 19.40 | < 0.0001 |
| AST | 13–26 (U/L) | 23.12 ± 9.79 | 18.14 ± 8.85 | 4.98 ± 11.85 | 0.002 |
| FBG | 3.5–5.5 (mmol/L) | 5.71 ± 3.14 | 4.85 ± 2.05 | 0.86 ± 2.18 | 0.006 |
| HbA1c | 4.8–6 (%) | 6.55 ± 2.61 | 5.48 ± 1.44 | 1.07 ± 1.59 | 0.001 |
| PTH | 15–65 (pg/mL) | 56.58 ± 23.23 | 52.83 ± 40.54 | 3.75 ± 42.30 | 0.77 |
| Uric Acid | 150–350 (mmol/L) | 355 ± 67.97 | 356 ± 85.52 | − 1.11 ± 38.58 | 0.93 |
M mean, SD standard deviation, Difference postoperative value minus preoperative value, TC total cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, TG total triglycerides, ALT alanine amino transferase, AST aspartate aminotransferase, FBG fasting blood glucose, HbA1c glycosylated hemoglobin
aMean follow-up = 24.2 ± 12.28 months
Evolution of cardiometabolic parameters of the sample
| Parameter | Preop | Postopa |
| Remission | De novo |
|---|---|---|---|---|---|
|
|
|
|
| ||
| TC | 10 (20.8) | 3 (6.3) | 0.06 | 13 (29.5) | 4 (9.1) |
| LDL | 11 (66.1) | 7 (38.9) | < 0.0001 | 8 (21.1) | 2 (5.37) |
| HDL | 12 (32.4) | 7 (18.9 | 0.27 | 37 (100) | 0 (0) |
| TG | 4 (10.3) | 1 (2.6) | 0.38 | 35 (83.3) | 0 (0) |
| ALT | 29 (45.3) | 7 (10.9) | < 0.0001 | 22 (75.9) | 0 (0) |
| AST | 14 (24.1) | 5 (8.6) | 0.03 | 12 (85.7) | 3 (5.2) |
| Prediabetes | 17 (12.6) | 4 (5.0) | < 0.0001 | 17 (100.0) | 0 (0) |
| T2DM | 10 (12.6) | 6 (7.6) | < 0.0001 | 8 (80.0) | 0 (0) |
| Uric acid | 6 (66.7) | 3 (33.3) | 0.25 | 3 (50.0) | 0 (0) |
| PTH | 4 (33.3) | 2 (16.7) | 0.63 | 3 (75.0) | 1 (8.3) |
TC total cholesterol, NA not applicable, LDL low-density lipoprotein, HDL high-density lipoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, T2DM type 2 diabetes
aMean follow-up = 24.2 ± 12.28 months
bMcNemar chi-squared test
cPercentage of participants with metabolic abnormality calculated as the number of participants (among those for whom sufficient data were available both preoperatively and postoperatively to determine whether the coexisting condition was present), divided by the number of participants (among those for whom sufficient data were available preoperatively and postoperatively)